Value of RAPID3 in patients with PsA: results from the TICOPA and LOPAS II databases

ConclusionRAPID3 appears comparably informative to PASDAS and DAPSA in PsA, with greater feasibility for routine clinical care.This article is protected by copyright. All rights reserved.

Source: Arthritis Care and Research - November 7, 2017 Category: Rheumatology Authors: Laura C Coates, William Tillett, Gavin Shaddick, Theodore Pincus, Arthur Kavanaugh, Philip S Helliwell Tags: Original Article Source Type: research